Advances in MR for imaging glymphatic system and disease metabolism.||学术交流|最新动态| 华西磁共振研究中心

Advances in MR for imaging glymphatic system and disease metabolism.

Topic: Advances in MR for imaging glymphatic system and disease metabolism

Moderator: Hong Zhang, Post.doc

Speaker 1: Yiqi Ma, Ph.D. Candidate

Supervisor: Prof. Min Wu

Speaker 2: Wanting Li, M.M. Candidate

Supervisor: Prof. Su Lui

Date: 9/12/2024, 14:00

Location: The lab of HMRRC (10011, the 8th Teaching Building)

Speaker 1: Yiqi Ma, Ph.D. Candidate

Title: Hyperpolarized ¹³C MRI: State of the Art and Future Directions

Keypoints：

Question: 1) How can hyperpolarized ¹³C MRI technology be used to detect and understand metabolic processes associated with human disease? 2) What is the current status and potential of hyperpolarized ¹³C MRI technology in clinical research and application? 3) What are the advantages of hyperpolarized ¹³C MRI compared to traditional imaging techniques such as PET?

Findings: 1) The hyperpolarized ¹³C MRI technique significantly enhances the MRI signal of ¹³C-labeled molecules, allowing real-time detection of enzyme-mediated metabolic processes associated with human disease. 2) Hyperpolarized ¹³C MRI technology has shown unique advantages and potential in monitoring early treatment effects in diseases such as prostate cancer, brain tumors and cardiometabolic diseases. 3) HP MRI with [1-¹³C]pyruvate provides information at a key branch point of metabolic pathways involved in downstream glucose metabolism—information that is not accessible to FDG PET. HP ¹³C probes can be imaged simultaneously to provide information on multiple metabolic processes while FDG PET can not.

Meaning: Hyperpolarized ¹³C MRI provides a new molecular imaging approach that can be used to better understand and detect metabolic changes in disease. This technique is expected to improve disease diagnosis, treatment monitoring and efficacy evaluation, especially in areas where traditional imaging techniques struggle to provide adequate information.

Speaker 2: Wanting Li, M.M. Candidate

Title: Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease

Keypoints：

Question: Can the dysfunction of the glymphatic system predict amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease?
Findings: This study suggests that glymphatic impairment indicated by the ALPS index may occur before significant Aβ deposits, and predict amyloid deposition, neurodegeneration, and clinical progression in AD. The analysis along the perivascular space (ALPS) index is reduced in patients with Alzheimer's disease (AD) dementia, prodromal AD, and preclinical AD. Lower ALPS index predicted accelerated amyloid beta (Aβ) positron emission tomography (PET) burden and Aβ-positive transition. The decrease in the ALPS index occurs before cerebrospinal fluid Aβ42 reaches the positive threshold. ALPS index predicted brain atrophy, clinical progression, and cognitive decline. Aβ PET and brain atrophy mediated the link of ALPS index with cognitive decline.
Meaning: This study demonstrates for the first time the predictive effect of the ALPS index on amyloid deposition, brain atrophy, clinical progression, and cognitive decline in AD, and the mediating effect of amyloid and neurodegeneration on the glymphatic–cognitive decline association.

返回上一级

回到首页

上一条：

下一条：Seminar: Fundamental functional differences between gyri and sulci: implications for brain function, cognition, and behavior

分享按钮